Oncocyte Corporation - Common Shares, No Par Value (OCX) Institutional Ownership

CUSIP: 68235C107

13F Institutional Holders and Ownership History from Q4 2015 to Q2 2025

Type / Class
Equity / Common Shares, No Par Value
Symbol
OCX on Nasdaq
Shares outstanding
28,495,649
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Investment Quick Answers

What is CUSIP 68235C107?
CUSIP 68235C107 identifies OCX - Oncocyte Corporation - Common Shares, No Par Value in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Significant Owners of Oncocyte Corporation - Common Shares, No Par Value (OCX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIO-RAD LABORATORIES, INC. 9.7% $608,097 2,764,078 BIO-RAD LABORATORIES, INC 10 Feb 2025
SMITH PATRICK W 10% $4,221,889 1,773,903 Patrick W. Smith 26 Dec 2024

Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q2 0 $0 -$126,921 0
2025 Q1 44,378 $126,921 -$7,722 $2.86 1
2024 Q4 47,078 $112,046 -$29,215 $2.38 1
2024 Q3 59,353 $169,156 -$3,224,887 $2.85 1
2024 Q2 1,152,395 $3,399,565 +$1,009,560 $2.95 2
2024 Q1 810,171 $2,373,801 -$46,191 $2.93 2
2023 Q4 825,936 $2,049,754 -$20,365 $2.49 2
2023 Q3 833,802 $2,716,547 -$68,395,020 $3.20 2
2023 Q2 91,821,550 $21,118,229 +$8,239,978 $0.23 45
2023 Q1 55,657,631 $19,725,177 -$1,788,149 $0.35 51
2022 Q4 60,727,357 $19,486,077 -$2,603,944 $0.32 55
2022 Q3 66,115,361 $48,286,884 -$1,938,715 $0.73 55
2022 Q2 68,689,787 $61,801,567 +$12,093,920 $0.90 64
2022 Q1 54,297,692 $81,004,102 -$2,234,275 $1.49 76
2021 Q4 55,309,802 $119,904,059 -$4,932,956 $2.17 82
2021 Q3 56,556,369 $201,842,971 -$4,273,319 $3.56 91
2021 Q2 56,557,145 $324,629,337 +$10,097,713 $5.74 88
2021 Q1 54,525,746 $282,982,492 +$112,979,747 $5.19 84
2020 Q4 32,820,981 $78,442,746 +$4,663,024 $2.39 56
2020 Q3 31,284,691 $43,477,422 -$4,537,534 $1.39 55
2020 Q2 32,913,612 $62,907,536 +$9,179,739 $1.91 57
2020 Q1 27,664,198 $67,748,452 +$4,418,527 $2.45 52
2019 Q4 25,884,634 $58,219,716 +$15,568,577 $2.25 50
2019 Q3 18,982,051 $39,859,066 +$6,042,313 $2.10 53
2019 Q2 15,958,159 $39,753,182 -$2,942,657 $2.49 48
2019 Q1 16,115,175 $63,651,620 +$30,829,652 $3.95 45
2018 Q4 8,316,794 $11,476,217 -$815,784 $1.38 14
2018 Q3 8,717,557 $21,792,392 -$155,396 $2.50 20
2018 Q2 8,778,305 $22,385,400 +$392,217 $2.55 24
2018 Q1 8,633,348 $18,127,749 +$8,211,749 $2.10 27
2017 Q4 4,675,016 $21,738,469 +$1,170,257 $4.65 32
2017 Q3 4,410,134 $33,296,650 +$3,970,096 $7.55 28
2017 Q2 3,900,811 $20,278,960 +$545,423 $5.19 30
2017 Q1 3,775,245 $22,466,000 +$4,356,561 $5.94 25
2016 Q4 3,124,915 $22,028,000 +$338,627 $7.05 24
2016 Q3 3,076,924 $15,505,000 +$7,596,691 $5.02 20
2016 Q2 1,582,033 $5,632,178 -$394,497 $3.56 24
2016 Q1 1,668,822 $7,688,812 +$2,644,415 $4.61 35
2015 Q4 1,094,163 $6,839,000 +$6,839,000 $6.24 4